On Friday, the FDA advisory committee is set to vote on the usage of a third Pfizer shot in people ages 16 and older.
As the data behind the third dose of the vaccine has shown contrasting reviews this week, the upcoming vote from the Food and Drug Administration’s vaccine committee on coronavirus booster shots could go either way.
FDA Vaccine Panel To Vote On Covid-19 Booster Shots
The committee is scheduled to vote by 4:45 p.m. on whether the Pfizer vaccine can be fully approved so that it becomes eligible for another shot.
The vaccine, known by the brand name Comirnaty, is being decided for another shot after six months after Americans have received the second shot in the two-dose vaccination.
The FDA has previously also overseen making important decisions that concern the vaccine, such as last year when it granted Pfizer’s vaccine with emergency authorization.
It is not essential for the FDA to always follow the advice of the committee, but many times it does. Earlier during the pandemic, the panel’s meetings to consider vaccine authorizations were mostly predominantly met with agreement, which ended in decisive votes in favor of the FDA.
The advisory committee of the FDA will vote Friday afternoon for a decision on whether a third shot of the Pfizer vaccine is needed for people ages 16 and older.
Experts predict that there is not enough substantial data yet through which a decision can be formed on additional Moderna or Johnson & Johnson doses.
There is less than a week left for Biden’s administration’s booster plan to begin, but the expert officials still lack the agreement of whether there is a need for a third dose or not.
There was an FDA review out this week, but it also seemed to not make a judgment call with the required data, stating, “there are many potentially relevant studies, but FDA has not done any independent review or verification of the available data and its conclusion.
An official from FDA stated that “ overall data indicate that currently The US-licenced or authorized corona vaccines can protect against extreme Covid-19 disease in the States.
On the other hand, Pfizer argues that a third dose is necessary for endorsement.
According to data released by the FDA, the manufacturing company claims that the third shot with a duration of six months after the second shot would “restore” protection from the coronavirus infection to approximately ninety-five percent.
Even after facing serious questioning and criticism from experts, the Biden administration has stood behind its plan.
The administration officials are debating and arguing over the needs and importance of booster shots. Many American citizens have come together and took the matter into their hands by taking booster shots even before clearance by the CDC.
Depending on how the FDA committee vote goes on Friday, the officials could decide to postpone Biden’s booster shot plan, with the possibility of only offering the third dose of the vaccine to the only at-risk population.